id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-N-0129-0005,FDA,FDA-2012-N-0129,"Agency Information Collection Activities; Submissions for Office of Management and Budget Review, Comment Request; General Licensing Provisions; Section 351(k) Biosimilar Applications",Notice,30 Day Proposed Information Collection,2012-05-24T04:00:00Z,2012,5,2012-05-24T04:00:00Z,2012-06-26T03:59:59Z,2015-01-21T17:13:12Z,2012-12591,0,0,090000648101b461
FDA-2012-N-0129-0002,FDA,FDA-2012-N-0129,Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions; Section 351(k) Biosimilar Applications; Correction,Notice,Correction,2012-02-23T05:00:00Z,2012,2,2012-02-23T05:00:00Z,,2015-01-21T17:11:14Z,2012-04168,0,0,0900006480fbeaab
FDA-2012-N-0129-0001,FDA,FDA-2012-N-0129,Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions; Section 351(k) Biosimilar Applications,Notice,60 Day Proposed Information Collection,2012-02-15T05:00:00Z,2012,2,2012-02-15T05:00:00Z,2012-04-17T03:59:59Z,2015-01-21T17:10:49Z,2012-03548,0,0,0900006480fb7292